Antibody-Drug Conjugate Design and Applications in Oligonucleotide Bioconjugation Development

Antibody-drug conjugates (ADCs) are an emerging class of biopharmaceuticals with therapeutic applications in oncology and beyond. ADCs combine a .. Read more monoclonal antibody conjugated to a highly potent cytotoxic payload via a suitable linker, that targets an antigen expressed in certain cancer cells. Antibody-oligonucleotide conjugates (AOCs) are a growing sub-class of ADCs that utilize the oligonucleotide functionality in combination with the antibody’s exquisite targeting ability and improved biodistribution profile. The development of AOCs is leading to therapeutic benefits, thereby extending the applications of bioconjugated drugs. However, the design of ADCs is complex with each of the three key components — the antibody, linker and payload — requiring optimization in early development. Drawing on their expertise in ADC construction, Abzena has developed a toolbox to aid screening and selection of the optimal ADC. Join this webinar for an overview of Abzena’s experiences in the ADC field, including the development and application of next-generation technologies, and their utility in the production of ADCs and AOCs.